- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update
Collegium Pharmaceutical (Nasdaq:COLL) today reported its financial results for the fourth quarter and year ended December 31, 2017 and provided a corporate update. As quoted in the press release: “In 2017, our focus on operational execution generated significant momentum with Xtampza ER,” said Joe Ciaffoni, Chief Operating Officer of Collegium. “In 2018, the Collegium team …
Collegium Pharmaceutical (Nasdaq:COLL) today reported its financial results for the fourth quarter and year ended December 31, 2017 and provided a corporate update.
As quoted in the press release:
“In 2017, our focus on operational execution generated significant momentum with Xtampza ER,” said Joe Ciaffoni, Chief Operating Officer of Collegium. “In 2018, the Collegium team is committed to continuing this focus so that patients who require opioid pain management can benefit from abuse-deterrent Xtampza ER, as well as the Nucynta franchise.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.